SPECIAL REPORT
MOST SHARED
- Europe May Be Unprepared for Greece Exit: Official
- Marc Faber: 100% Chance of Global Recession
- As Bank Loans Dry Up in Spain, Small and Medium Businesses Fight for Life
- Where Large Banks Fail, Regionals are Succeeding: Bove
- Facebook Analyst Reports All Over the Map
- How Nasdaq Lost Control of Facebook IPO, by the Minute
- RIM May Cut at Least 2,000 Jobs in Restructuring: Report
- How Boaz Weinstein and Hedge Funds Outsmarted JPMorgan
- China Market Lookahead: Stocks Set for More Weakness
- Steve Jobs and Mickey Drexler: A Tale of Two Retailers
- A New Look at the ‘New Poor’
- Six Pack: Beer Buzz of the Week
- Greek Exit Could Trigger 50% Fall in Euro Stocks: Analyst
- Under Pressure, FHA Skews to Wealthier Home Buyers
- Big Stock Upside for Hudson City Deal: Analyst
- 5 High-Yield Stocks Ready to Boost Dividends
- Yoshikami: Four Things You Need to Know About Gold Now
- Steinbock: The Euro Zone Endgame Begins
- Option Bulls Take Another Shot on Idenix
- How Weinstein, Hedge Funds Outsmarted JPMorgan
- How Nasdaq Lost Control of Facebook IPO, by the Minute
- Week Ahead: Europe Has Wall Street Bull on Short Leash
- Citigroup Lost $20 Million on Facebook IPO Trades
- JPMorgan to Shake Up Risk Team After Big Loss: Report
- RIM May Cut at Least 2,000 Jobs in Restructuring: Report
- EU Finalizes Bank Reforms; Shifts Burden to Bondholders
- Spain's Bankia Eyes Stake Sales After Record Bailout
- EU Set to Launch Action Against China Over Telecom Aid
RSS FEED
Pharma's Market
Text Size 
The Novartis Apprentice: You're Hired!
 |
That's the question I'm asking after Novartis announced that it's tapped a managing director of investment banking at Goldman Sachs, Jonathan Symonds, as its CFO apprentice.
Okay, that's what I'm calling him. Novartis refers to the 50-year-old Symonds as "deputy CFO and as CFO designate." So, starting September 1st Symonds is going to shadow the current CFO Raymond Breu until he retires on March 31st next year. Breu, who is turning 65, has been with NVS for 35 years. That kind of longevity at a single company is almost unheard of these days.
Before working at Goldman, Symonds was CFO at AstraZeneca for eight years where, according to Novartis' press release, his duties included strategy and mergers and acquisitions. Of course, M&A is the name of the game in big pharma right now. So far this year, Pfizer's buying Wyeth, Merck's buying Schering-Plough and Roche bought Genentech. So, who's next?
In an exclusive interview with NVS Chairman and CEO Dr. Daniel Vasella last week I asked him about the current consolidation wave and whether he'd get caught up in it. Beyond the Nestle/Alcon deal, Dr. Vasella would only say, "The future will tell." Well, one week into the future, he's gone out and hired an investment banker as his CFO.
Coincidentally, JPMorgan pharma analyst Chris Schott is out with a research note for clients today titled, "Perspective On The Next Pharma Deal." He thinks the two major American drug companies that haven't done a mega deal (yet), Bristol-Myers Squibb and Eli Lilly, will probably do "small/mid-sized transactions." Some analysts and investors have speculated the two might hook up, but it's just rumor and speculation at this point. Schott points out that BMY has around $9 billion in "gross cash" and LLY has nearly $5 billion.
They're not the only ones sitting on a bunch of cash. Pretty much all of the big pharmas have a significant amount of spending money. And soon NVS will have an investment banker at the helm, with a pharma background to boot, to help the company figure out where to put its capital to work.
Questions? Comments? and follow me on Twitter at mhuckman
Data is a real-time snapshot *Data is delayed at least 15 minutes
